20th week of 2020 patent applcation highlights part 26 |
Patent application number | Title | Published |
20200148710 | LITHIUM BORON FLUOROPHOSPHATE COMPLEX COMPOUND, LITHIUM BORON FLUOROPHOSPHATE-CONTAINING COMPOSITION, LITHIUM BORON FLUOROPHOSPHATE, ADDITIVE FOR LITHIUM SECONDARY BATTERY, NON-AQUEOUS ELECTROLYTIC SOLUTION FOR BATTERY, AND LITHIUM SECONDARY BATTERY - A lithium boron fluorophosphate complex compound including a compound A that is one selected from a group of lithium boron fluorophosphates represented by Formula (I), and a compound B that is one selected from a group of compounds represented by Formulae (II) to (IX). R | 2020-05-14 |
20200148711 | DIMETHYLAMMONIUM-CONTAINING PEROVSKITE DEVICES - The present disclosure relates to a perovskite that includes ABX | 2020-05-14 |
20200148712 | Ruthenium Precursors For ALD And CVD Thin Film Deposition And Uses Thereof - Metal coordination complexes comprising a metal atom coordinated to at least one diazabutadiene ligand having a structure represented by: | 2020-05-14 |
20200148713 | RAW MATERIAL FOR VAPOR DEPOSITION INCLUDING ORGANOPLATINUM COMPOUND AND VAPOR DEPOSITION METHOD USING THE RAW MATERIAL FOR VAPOR DEPOSITION - A raw material for vapor deposition for producing a platinum thin film or a platinum compound thin film by a vapor deposition method. The raw material for vapor deposition includes an organoplatinum compound represented by the following formula, in which a cyclopentene-amine ligand and an alkyl ligand are coordinated to divalent platinum. The organoplatinum compound of the present invention has moderate thermal stability and can respond flexibly to severe film formation conditions, including a wider film formation area, higher throughput, and the like. | 2020-05-14 |
20200148714 | MULTIPLE COUPLING & OXIDATION METHOD - The present invention relates to the field of stereodefined phosphorothioate oligonucleotides and to stereodefining nucleoside monomers and methods of synthesis of stereodefined oligonucleotides using said monomer. Herein are disclosed oligonucleotide enhanced synthesis methods where within a single elongation cycle there are repeated coupling and oxidation steps. The method results in an enhanced yield and higher purity of stereodefined phosphorothioate oligonucleotides | 2020-05-14 |
20200148715 | SWEETENER AND SWEETENED COMPOSITIONS INCORPORATING REBAUDOSIDE N - Sweetener compositions including at least 3% Rebaudioside N by weight based on the total weight of sweetener compounds in the sweetener composition are disclosed. The sweetener compositions are used to prepare sweetened compositions including food, beverages, dental products, pharmaceuticals, and nutriceuticals. Disclosed are methods of preparing sweetener compositions and sweetened compositions including Rebaudioside N, providing improved sweetener flavors, including providing a sugar-like flavor and temporal profile to sweetener and sweetened compositions. | 2020-05-14 |
20200148716 | AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING - Compositions including derivatives of spinosyns and methods for the production of derivatives of spinosyns are provided. The spinosyn derivatives described herein include those functionalized on the C-5,6 double bond to provide an aziridine ring system. The method produces spinosyn derivatives that exhibit activity towards insects, arachnids, and nematodes and are useful in the agricultural and animal health markets. | 2020-05-14 |
20200148717 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as treatments of diseases. | 2020-05-14 |
20200148718 | PHARMACEUTICAL-GRADE 20-HYDROXYECDYSONE EXTRACT, USE OF SAME AND PREPARATION THEREOF - The invention concerns a method for preparing an extract from a preparation of approximately 90% pure 20-hydroxyecdysone that comprises the following steps:
| 2020-05-14 |
20200148719 | ION EXCHANGE CHROMATOGRAPHY WITH IMPROVED SELECTIVITY FOR THE SEPARATION OF POLYPEPTIDE MONOMERS, AGGREGATES AND FRAGMENTS BY MODULATION OF THE MOBILE PHASE - Herein is reported a method for producing a polypeptide in monomeric form comprising the following step: recovering the polypeptide in monomeric form from an ion exchange chromatography material by applying a solution comprising a non-ionic polymer and an additive. | 2020-05-14 |
20200148720 | A PEPTIDE CAPABLE OF FORMING A GEL FOR USE IN TISSUE ENGINEERING AND BIOPRINTING - The present invention relates to peptides capable of forming a gel and to their use in tissue engineering and bioprinting. The present invention furthermore relates to a gel comprising a peptide in accordance with the present invention, to a method of preparing such gel and to the use of such gel. In one embodiment, such gel is a hydrogel. The present invention furthermore relates to a wound dressing or wound healing agent comprising a gel according to the present invention and to a surgical implant or stent comprising a peptide scaffold formed by a gel according to the present invention. Moreover, the present invention also relates to a pharmaceutical and/or cosmetic composition, to a biomedical device or an electronic device comprising the peptide according to the present invention. | 2020-05-14 |
20200148721 | PEPTIDE SHOWING MELANOGENESIS PROMOTING ACTIVITY AND USE THEREOF - The present invention provides a peptide exhibiting melanogenesis promoting activity. A peptide according to the present invention increases the activity and expression of tyrosinase and the expression of factors involved in melanogenesis, thereby exhibiting an outstanding effect on melanogenesis. The peptide of the present invention can be used for the prevention, alleviation, and treatment of hypomelanosis. The outstanding activity and stability stated above allow the peptide of the present invention to be very favorably applied to medicines, quasi-medicines, and cosmetics. | 2020-05-14 |
20200148722 | ANTI-INFLAMMATORY USE OF PEPTIDE - Provided a peptide of the sequence Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys or a salt thereof for use in the treatment of inflammation, of an inflammatory disorder and/or of ion thea condition characterized by inflammation, including wounds, burns, psoriasis, acne and atopic dermatitis. | 2020-05-14 |
20200148723 | Malacidins and Methods of Use - The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, and related conditions. The invention provides compositions and methods incorporating and utilizing malacidin antibiotics, and derivatives and variants thereof. | 2020-05-14 |
20200148724 | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONSIVE BIOPOLYMER NETWORKS - Disclosed herein are partially ordered polypeptides, which include a plurality of disordered domains and a plurality of structured domains. The partially ordered polypeptides may have phase transition behavior and form aggregates at, above, or below certain temperatures. Further provided are cellular scaffolds comprised of the partially ordered polypeptides. | 2020-05-14 |
20200148725 | NOROVIRUS FUSION PROTEINS AND VLPS COMPRISING NOROVIRUS FUSION PROTEINS - Nucleic acids encoding norovirus VP1 fusion proteins and VLPs comprising the norovirus VP1 fusion proteins are provided. Methods for norovirus VP1 fusion protein and norovirus VLP production in plants are also described. The VP1 fusion protein comprises, a first sequence encoding an S domain derived from a first norovirus strain, and a second sequence encoding a P domain derived from a second norovirus strain. | 2020-05-14 |
20200148726 | MULTI-EPITOPE FUSION PROTEIN OF AN HCV ANTIGEN AND USES THEREOF - The disclosure relates to a multi-epitope fusion protein as well as to its use as calibrator and/or control in an in vitro diagnostics immunoassay for detecting HCV core antigen. The multi-epitope fusion protein has two to six different non-overlapping linear peptides present in the amino acid sequence of hepatitis C virus (HCV) core protein, wherein each of the peptides is separated from the other peptides by a spacer consisting of a non-HCV amino acid sequence and having a chaperone amino acid sequence. No further HCV specific amino acid sequences are present in the polypeptide. A further aspect relates to a reagent kit for detecting HCV core antigen containing said multi-epitope fusion protein as calibrator or control or both. | 2020-05-14 |
20200148727 | AMINO ACID-SPECIFIC BINDER AND SELECTIVELY IDENTIFYING AN AMINO ACID - An amino acid-specific binder selectively binds to a binding amino acid. A binder complex selectively identifies the binding amino acid and includes an adjunct attached to the amino acid-specific binder. The adjunct includes a taggant, protein, substrate, or chemical modifier. Selectively identifying an N-terminal amino acid includes anchoring a C-terminal end; contacting an N-terminal amino acid of the anchored analyte with the binder complex; selectively binding when the N-terminal amino acid includes the binding amino acid; producing, by the taggant of the tagged complex, a taggant signal; detecting the taggant signal; and identifying the N-terminal amino acid based on the taggant signal. | 2020-05-14 |
20200148728 | PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS - The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis. | 2020-05-14 |
20200148729 | Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections - Provided herein are fusion polypeptides comprising at least two Mycobacterial antigens, wherein one Mycobacterial antigen is a strong central memory T cell activator, and wherein one Mycobacterial antigen is a strong effector memory T cell activator. Also provided herein are methods of making and using such fusion polypeptides for the prevention or treatment of a secondary | 2020-05-14 |
20200148730 | Polypeptides Having Cellulolytic Enhancing Activity And Nucleic Acids Encoding Same - The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 2020-05-14 |
20200148731 | C4BP-BASED COMPOUNDS FOR TREATING IMMUNOLOGICAL DISEASES - The invention relates to compounds for use in the prevention and/or treatment of immunological diseases, particularly rheumatoid arthritis systemic lupus erythematosus and lupus nephritis, characterized by the subcutaneous administration of isoforms of C4BP lacking the beta chain or polypeptides comprising the CCP6 region of the alpha chain of C4BP no more than once a week or at a dose ranging from 0.24 mg/m | 2020-05-14 |
20200148732 | SMALL MOLECULES BLOCKING HISTONE READER DOMAINS - The present invention relates to small molecules interfering with the conformational space of the TONSL ARD occupied by the histone H4 tail. These small molecules targets the binding pocket of TONSL encompassing the H4 residues K12-R23 and act by preventing or disrupting the binding of the H4 tail K12-R23 with the TONSL ARD via direct competition or via allosteric disruption of the binding pocket. | 2020-05-14 |
20200148733 | NOVEL INTERLEUKIN-17A-SPECIFIC AND INTERLEUKIN-23-SPECIFIC BINDING POLYPEPTIDES AND USES THEREOF - The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides. | 2020-05-14 |
20200148734 | Compositions and Methods for Improving Resistance to Breakage and Eggshell Strength - Described herein are FGF-23 epitope peptides, methods of producing antibodies in laying hens by injecting the peptides, and methods of improving resistance to eggshell breakage and/or increasing eggshell strength by administering an FGF-23 epitope peptide to a laying hen. | 2020-05-14 |
20200148735 | METHOD FOR IN VITRO GLYCOENGINEERING OF AN ERYTHROPOIESIS STIMULATING PROTEIN - The present invention relates to a method for the production of in vitro glycoengineered erythropoiesis stimulating protein, comprising the steps of providing sialic acid free erythropoiesis stimulating protein, treating the erythropoiesis stimulating protein with N-Acetyl-Glucosamin-transferase B3GNT2, treating the erythropoiesis stimulating protein with galactosyltransferase, and treating the erythropoiesis stimulating protein with sialyltransferase. | 2020-05-14 |
20200148736 | GM-CSF Variants and Methods of Use - GM-CSF variants, polynucleotides encoding them, and methods of making and using the foregoing are useful in treatment of immune-related disorders, such as inflammatory bowel disease (IBD). | 2020-05-14 |
20200148737 | THERAPEUTIC COMPOUNDS AND METHODS - This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain. | 2020-05-14 |
20200148738 | NYESO TCR - The present invention relates to an isolated T cell receptor (TCR) specific for NY-ESO-1/LAGE-1 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer. | 2020-05-14 |
20200148739 | T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS - Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal. | 2020-05-14 |
20200148740 | ANTITUMOR PEPTIDE AND USE THEREOF - An antitumor peptide provided according to the present invention includes | 2020-05-14 |
20200148741 | ISOLATED PEPTIDES DERlVED FROM THE B7 LlGAND DlMER INTERFACE AND USES THEREOF - Disclosed are peptides comprising amino acid residues of the dimer interface of human B7-1 and B7-2 and compositions and uses thereof. | 2020-05-14 |
20200148742 | EXPRESSION OF NKG2D ACTIVATING LIGAND PROTEINS FOR SENSITIZING CANCER CELLS TO ATTACK BY CYTOTOXIC IMMUNE CELLS - Provided is a recombinant viral vector that expresses a NKG2D activating ligand, such as a UL-16 binding protein. When introduced into a cancer cell, the vector can cause expression of the NKG2D activating ligand, thereby overcoming repression of NK-mediated (or other effector cell, e.g., macrophage) cytotoxicity and causing effector cell-mediated death of the cancer cell. Expression of the NKG2D activating ligand can be controlled by a miRNA present in greater concentration in noncancerous cells than in cancer cells, which can permit selective expression of the ligand in cancer cells and reduced cytotoxicity toward noncancerous cells. The vector can cause expression of an oncolytic factor. When formulated into a pharmaceutical composition and administered to a patient, the vector can be used to treat cancer. The cancer can be a glioma, such as glioblastoma including one with an isocitrate dehydrogenase (IDH) mutation. The vector can be a herpes simplex virus vector, among others. | 2020-05-14 |
20200148743 | HLA-G TRANSCRIPTS AND ISOFORMS AND THEIR USES - Embodiments of the disclosure pertain to the field of HLA-G molecules and their therapeutic use. The disclosure pertains to new HLA-G isoforms, that is to say new RNA transcripts and proteins deriving from the HLA-G gene, pharmaceutical composition comprising thereof, as well as primers specific of these transcripts and antibodies specific of these proteins. The disclosure further pertains to the diagnostic or therapeutic use of these molecules. | 2020-05-14 |
20200148744 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF - The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory polypeptide that exhibits reduced binding affinity to a cognate co-immunomodulatory polypeptide. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual. | 2020-05-14 |
20200148745 | GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE - The disclosure relates to optimized polynucleotide sequences for LAMP-2B, expression cassettes, vectors, and methods of use thereof in treating disease, e.g. Danon disease. | 2020-05-14 |
20200148746 | NOVEL EXOSOME-BASED ANTICANCER AGENT - The present invention provides a recombinant exosome and uses thereof. More particularly, the present invention privides a recombinant exosome wherein a phagocytosis promoting protein is presented on the surface thereof. | 2020-05-14 |
20200148747 | CELL SHEET EMBEDDING AGENT, CELL SHEET-CONTAINING COMPOSITION, AND KIT - An object of the present invention is to provide a cell sheet embedding agent, which makes it possible to stably transport a cell sheet at the time of transport at a low temperature and to collect the cell sheet from the cell sheet embedding agent in a simple manner after being transported, a cell sheet-containing composition, and a kit. According to the present invention, there is provided a cell sheet embedding agent containing a polypeptide represented by the following Formula 1, in which in a case where a molecular weight distribution of the polypeptide is measured, a peak area of a maximum molecular weight is equal to or greater than 80% of the total peak area of all molecular weights. | 2020-05-14 |
20200148748 | THERAPEUTIC VARIANT ALPHA-2-MACROGLOBULIN COMPOSITIONS - A2M polypeptide compositions containing a non-natural bait region are disclosed. Methods of producing wild-type and variant A2M polypeptides and polynucleotides containing a non-natural bait region are also disclosed. The bait regions of the variant A2M polypeptides demonstrate enhanced protease inhibitory characteristics compared to wild-type A2M. Variant A2M polypeptides that demonstrate longer half-lives upon administration to an organism compared to wild-type A2M are disclosed. The A2M compositions are useful in treating a number of diseases and conditions including inflammation, chronic wounds, and diseases with a pathology associated with proteases. | 2020-05-14 |
20200148749 | ANTIBODIES AND PROCESSES FOR PREPARING THE SAME - Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins. | 2020-05-14 |
20200148750 | Ebola Virus Antibodies and Binding Agents Derived Therefrom - This disclosure relates to antibodies and antigen binding fragments that specifically bind Ebola virus particles. In certain embodiments, the antibodies and fragments are capable of treating or preventing an Ebola viral infection. In certain embodiments, the antibodies and antigen binding fragments are also contemplated for diagnostic methods and compositions related thereto. | 2020-05-14 |
20200148751 | HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN - The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines. | 2020-05-14 |
20200148752 | Methods of Treating Inflammatory Pain - The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of inflammatory pain and/or symptoms of inflammatory pain, and to a method of treating and/or preventing inflammatory pain and/or symptoms of inflammatory pain using an anti-CGRP antibody. | 2020-05-14 |
20200148753 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR DEMENTIA | 2020-05-14 |
20200148754 | ANTI-C5A ANTIBODIES AND USES THEREOF - This invention relates to inhibition of the complement signaling using an anti-C5a antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5a antibody. | 2020-05-14 |
20200148755 | ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF - The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies. | 2020-05-14 |
20200148756 | ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF PREVIOUSLY TREATED BREAST CANCER - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, in combination with one or more additional anti-tumor therapeutic agents in previously treated metastatic breast cancer. | 2020-05-14 |
20200148757 | CONJUGATE OF VEGF-GRAB PROTEIN AND DRUG, AND USE THEREOF - The present invention relates to a VEGF-Grab protein-drug conjugate and a use thereof and, more particularly, to a conjugate of a fusion protein in which a VEGFR1 domain 2, a VEGFR1 domain 3, and an antibody fragment are connected and a drug, a pharmaceutical composition for prevention or treatment of cancer or angiogenesis-related disease, comprising the conjugate, and a method for prevention or treatment of cancer or angiogenesis-related disease. Serving as a multi-paratopic VEGF decoy receptor, the conjugate including a VEGF-Grab protein and a drug of the present invention can be used as a multi-purpose platform for treatment of cancer or angiogenesis-related disease. | 2020-05-14 |
20200148758 | THERAPEUTIC COMBINATIONS COMPRISING EOSINOPHIL-DEPLETING ANTIBODIES AND USES THEREOF - Anti-cancer immune-stimulating therapies have shown inconsistent results when used in humans. The present disclosure provides methods of using eosinophil-depleting agents to increase the therapeutic activity of anti-cancer immune-stimulating therapies. The present disclosure also provides methods of identifying subjects susceptible to respond to anti-cancer immune-stimulating therapies based on their ability to reduce the number of tumor regulatory T cells. | 2020-05-14 |
20200148759 | USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASE - The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1β binding antibody or functional fragment thereof. | 2020-05-14 |
20200148760 | METHOD FOR PREDICTING AND EVALUATING THERAPEUTIC EFFECT IN DISEASES RELATED TO IL-6 AND NEUTROPHILS - It has become clear that the therapeutic effect of an IL-6 inhibitor for IL-6- and neutrophil-associated diseases can be predicted using the expression level of neutrophil-associated genes as an indicator. It has also become clear that an IL-6 inhibitor is effective for the treatment of IL-6- and neutrophil-associated diseases in patients with high expression levels of neutrophil-associated genes. The present invention provides a method for selecting cases of IL-6- and neutrophil-associated diseases in which treatment with an IL-6 inhibitor is effective, as well as a method for effectively treating patients with IL-6- and neutrophil-associated diseases and with high expression levels of neutrophil-associated genes. | 2020-05-14 |
20200148761 | PREVENTING, TREATING, AND REDUCING (PERSISTENT) POST-TRAUMATIC HEADACHE - Disclosed herein are methods of treating or reducing incidence of post-traumatic headache and/or at least one secondary symptom associated with post-traumatic headache in a subject comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described. | 2020-05-14 |
20200148762 | METHODS FOR REGULATING ENDOGENOUS PRODUCTION OF ANTIBODIES AGAINST INFECTIOUS DISEASES - The present disclosure relates to the composition of one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for upregulating production of two or more antibodies, one or more bi-specific antibodies, or combinations thereof. Embodiments of the present disclosure can be used as a therapy or a treatment of a conditions including: sepsis, parasites, and active and chronic infections caused by bacteria, non-hemorrhagic viruses, amoeba, mycoplasma, fungus, prions or combinations thereof. | 2020-05-14 |
20200148763 | Cellular Delivery of DNA Intercalating Agents - Compositions and methods for targeted delivery of active agents to cells are provided. The compositions comprise a wholly or partially double-stranded synthetic DNA carrier, and an active agent intercalated in double-stranded portions of the DNA carrier. The DNA carrier may also be linked to a targeting agent. The compositions are useful for delivering an active agent into a targeted cell type, for example a cytotoxic agent. | 2020-05-14 |
20200148764 | CROSS-LINKERS AND THEIR USES - Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same. | 2020-05-14 |
20200148765 | ANTI-CLDN-5 ANTIBODY, AND DRUG CONTAINING SAID ANTIBODY - An object of the present invention is to provide a novel molecule which has high specificity to CLDN-5 and recognizes an extracellular domain of CLDN-5. The object is achieved by an antibody which specifically recognizes a three-dimensional structure or a primary structure of an extracellular domain of a Claudin-5 protein. | 2020-05-14 |
20200148766 | METHODS AND COMPOSITIONS FOR TREATING ALLERGIC OCULAR DISEASES - The present disclosure provides methods for the treatment of an allergic ocular disease (e.g., allergic conjunctivitis, keratoconjunctivitis, or giant papillary conjunctivitis). In particular, the present disclosure provides methods for the treatment of an allergic ocular disease through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of an allergic ocular disease. | 2020-05-14 |
20200148767 | ANTI-CD33 ANTIBODIES AND USES THEREOF - Anti-CD33 antibodies are described. The anti-CD33 antibodies can bind within the V-set Ig-like domain or the C2-set Ig-like domain of CD33. Epitopes on the C2-set Ig-like domain can provide a “pan-binding” site, to which the cognate antibody will bind regardless of whether the CD33 molecule also contains the V-set domain (as in, for example, CD33 | 2020-05-14 |
20200148768 | ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1 AND THE THERAPEUTIC USES THEREOF - Provided herein are molecules having an antigen binding fragment that immuno specifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immuno specifically binds to BTN1A1 dimers, such as anti-BTN1A1 dimer antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics. | 2020-05-14 |
20200148769 | ANTI-PVRIG ANTIBODIES AND METHODS OF USE - The present invention is directed to anti-PVRIG antibodies and methods of using same. | 2020-05-14 |
20200148770 | ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3) - The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (TIM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease. | 2020-05-14 |
20200148771 | INDUCIBLE MONOVALENT ANTIGEN BINDING PROTEIN - Disclosed herein are inducible monovalent target-binding proteins which are activated upon protease cleavage. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided. | 2020-05-14 |
20200148772 | ANTI-PD-L1 NANOBODY, CODING SEQUENCE AND USE THEREOF - Provided in the present invention are a type of anti-human PD-L1 specific nanobodies and VHH chains thereof, coding sequences of the foregoing nanobodies or VHH chains thereof, corresponding expression vectors and host cells, and a method for producing antibodies. | 2020-05-14 |
20200148773 | ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION - A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation. | 2020-05-14 |
20200148774 | Anti-CLL-1 Antibodies and Methods of Use - The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same. | 2020-05-14 |
20200148775 | SUBTYPES OF HUMANIZED ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR - An antibody subtype (1) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which one C-terminal of the heavy chain is Pro-NH | 2020-05-14 |
20200148776 | COMPOSITIONS AND METHODS FOR NON-MYELOABLATIVE CONDITIONING - Disclosed herein are non-myeloablative antibody-toxin conjugates and compositions that target cell surface markers, such as the CD34, CD45 or CD117 receptors, and related methods of their use to effectively conditioning a subject's tissues (e.g., bone marrow tissue) prior to engraftment or transplant. The compositions and methods disclosed herein may be used to condition a subject's tissues in advance of, for example, hematopoietic stem cell transplant and advantageously such compositions and methods do not cause the toxicities that are commonly associated with traditional conditioning methods. | 2020-05-14 |
20200148777 | CANCER-ASSOCIATED IMMUNOSUPPRESSION INHIBITOR - The present invention relates to a glyco-engineered Fc fragment-bearing compound for its use as an immunosuppression inhibitor in the treatment of a cancer-associated immunosuppression. The invention further relates to a pharmaceutical composition comprising at least this glyco-engineered Fc fragment-bearing compound. | 2020-05-14 |
20200148778 | ANTI-CD40 ANTIBODY, ANTIGEN BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF - Provided are an anti-CD40 antibody, an antigen binding fragment thereof, and a medical use thereof. Also provided are a chimeric antibody and a humanized antibody including a CDR region of the anti-CD40 antibody, a pharmaceutical composition including the human anti-CD40 antibody and the antigen binding fragment thereof, and an application thereof as an anti-cancer drug. In particular, provided are a humanized anti-CD40 antibody, and an application thereof in preparation of a drug to treat a CD40-mediated disease or disorder. | 2020-05-14 |
20200148779 | MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH - Modified IgG1 Fc domains having reduced binding to Fc-gamma-receptors are provided. Further provided are fusion polypeptides comprising a modified IgG1 Fc domain. An antibody polypeptide that specifically binds a human CD40 is provided, wherein the antibody polypeptides are fusions of a domain antibody (dAb) comprising a single V | 2020-05-14 |
20200148780 | CD 14 ANTAGONIST ANTIBODIES FOR TREATING NEURODEGENERATIVE DISEASES - This invention relates generally to agents and methods for treating the development or progression of a neurodegenerative disease. In particular, the present invention relates to CD14 antagonists for use in treating the development or progression of a neurodegenerative disease, including Motor Neurone Disease (MND) and Dementia disease or associated symptoms. The present invention further provides compositions including such agents. | 2020-05-14 |
20200148781 | NOVEL CD73 ANTIBODY, PREPARATION AND USES THEREOF - The present invention relates to improved anti-CD73 antibodies which, in comparison to prior art anti-CD73 antibodies bind to a membrane-bound form of CD73 protein having cancer-promoting role and inhibit its enzymatic activity, while essentially not inhibiting a soluble form of CD73 protein involved in cardioprotection. The present invention further relates to methods of generation of such specific anti-CD73 antibodies and uses thereof including uses as medicaments and in methods for treatment, amelioration, prophylaxis and diagnostics of cancer. | 2020-05-14 |
20200148782 | Control of Trace Metals During Production of Anti-CD38 Antibodies - The disclosure relates to methods to control trace metals during production of anti-CD38 antibodies, drug substances and drug products generated using the methods, and uses of the generated drug substances and drug products. | 2020-05-14 |
20200148783 | METHODS AND COMPOSITION FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES - The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof. | 2020-05-14 |
20200148784 | COMPOSITIONS AND METHODS RELATED TO xCT ANTIBODIES - Certain embodiments are directed to therapeutic compositions having an xCT specific antibody. | 2020-05-14 |
20200148785 | PD-L1 AND TA-MUC1 ANTIBODIES - The present invention relates to an antibody which effects enhanced T cell activation in comparison to a reference antibody being glycosylated including more than 80% core-fucosylation and wherein T cell activation is effected by an antibody characterized by enhanced binding to Fc#RIIIa. Said antibody is glycosylated, but essentially lacks core-fucosylation. | 2020-05-14 |
20200148786 | NK CELL-ACTIVATING FUSION PROTEIN, NK CELL, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME - The present invention relates to a fusion protein for cancer treatment and a use thereof. | 2020-05-14 |
20200148787 | BISPECIFIC ANTIBODIES FOR FACTOR IX AND FACTOR X - Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A. | 2020-05-14 |
20200148788 | METHODS FOR INCREASING THERMOGENIC ADIPOCYTES - In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes. | 2020-05-14 |
20200148789 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY ARTERIAL HYPERTENSION - It has been established that inhibition of the expression and function of nicotinamide phosphoribosyltransferase (NAMPT) can treat Pulmonary Arterial Hypertension (PAH) in a patient in need thereof. Compositions and methods of an effective amount of one or more inhibitors of intracellular NAMPT (iNAMPT), extracellular NAMPT (eNAMPT), or a receptor of eNAMPT, to treat PAH are provided. The compositions and methods reduce, or reverse the physiological vascular changes associated with the onset and progression of PAH. Inhibitors of NAMPT or receptors of NAMPT include small molecules, antibodies and antigen binding fragments thereof. Dosage forms including monoclonal antibody inhibitors of NAMPT or NAMPT receptors in an amount between 10 mg and 400 mg are provided. Dosage forms including small molecule inhibitors of NAMPT in an amount between 10 mg/kg and 3.5 mg/kg body weight of the recipient are also provided. | 2020-05-14 |
20200148790 | GLYCOSYLATION OF VARIABLE IMMUNOGLOBULIN DOMAINS - The present invention provides nucleotide sequences encoding polypeptides comprising immunoglobulin variable domains with engineered glycosylation acceptor sites. Specifically, the invention provides immunoglobulin variable domain proteins modified with selected glycans and specific glycan-conjugates thereof. Also provided herein are methods for the production of glycosylated immunoglobulin variable domains and glycan-conjugates thereof. | 2020-05-14 |
20200148791 | Method of Generating Anti-Linaclotide Antibodies and Uses Thereof - The invention provides a method for producing anti-linaclotide antibodies or antigen fragments thereof and uses thereof. | 2020-05-14 |
20200148792 | PRODUCTS FROM STEVIA RABAUDIANA - Various organic molecules, ingredients and compositions are prepared from | 2020-05-14 |
20200148793 | PURIFICATION OF OLIGOSACCHARIDES - The invention relates to separation of disaccharides from tri- or higher oligosaccharides by nanofiltration. | 2020-05-14 |
20200148794 | AMINE COMPOUND, MODIFIED CONJUGATED DIENE-BASED POLYMER CONTAINING FUNCTIONAL GROUP DERIVED THEREFROM, AND METHOD OF PREPARING THE MODIFIED CONJUGATED DIENE-BASED POLYMER - The present invention relates to a modified conjugated diene-based polymer containing a functional group derived from a tertiary amine compound represented by Formula 1, a method of preparing the same, and a tertiary amine compound represented by Formula 1. | 2020-05-14 |
20200148795 | STYRENE-FREE COATING COMPOSITIONS FOR PACKAGING ARTICLES SUCH AS FOOD AND BEVERAGE CONTAINERS - A method of forming a coating on a food or beverage container, which includes spraying a coating composition onto an interior surface of the food or beverage container, where the coating composition includes an emulsion-polymerized latex copolymer having copolymer chains of one or more ethylenically-unsaturated monomers and one or more styrene offset monomers. Preferably, the coating composition is substantially free of BPA, PVC, and styrene. The method may also include curing the sprayed coating composition, thereby providing the coating on the interior surface of the food or beverage container. | 2020-05-14 |
20200148796 | Drawn Articles of Low MTI Metallocene Polypropylene and Process to Produce Such Drawn Articles - The invention relates to drawn articles selected from fibres, tapes, yarns, staple fibres and continuous filaments, the articles comprising a polypropylene having a melt flow index in the range from 0.1 to 4.9 g/10 min as determined according to ISO 1133, condition L, at 230° C. with a load of 2.16 kg.; a xylene soluble fraction of at most 0.8 wt %, relative to the total weight of the polypropylene as determined in accordance with ASTM D542-98 ; a molecular weight distribution Mw/Mn ranging from 2.0 to 5.0; and a melting temperature Tm of at most 155° C. as determined according to ISO 3146. The invention also relates to the process to produce such drawn articles. | 2020-05-14 |
20200148797 | POLYMER, COMPOSITE POSITIVE ACTIVE MATERIAL INCLUDING THE SAME, AND LITHIUM SECONDARY BATTERY INCLUDING ELECTRODE INCLUDING THE POSITIVE ACTIVE MATERIAL - A polymer includes a repeating unit represented by at least one of Formula 1a or Formula 1b: | 2020-05-14 |
20200148798 | Functional Polyisobutylene-Containing Oligomers and Polymers - A method of making functional polyisobutylene (PIB)-containing oligomers and polymers. By the disclosed method, the synthesis of functional PIB-containing polymers can be achieved directly under cationic polymerization conditions and does not include any post-polymerization reactions. The desired functionality is introduced by direct Electrophilic Aromatic Substitution (EAS) reaction using substituted phenyl ring carrying desirable functionalities that do not react with Lewis acid but have weak association with Lewis acid, which still allow living polymerization and EAS reaction under living cationic polymerization conditions. In the disclosed method functional polyisobutylene or isobutylene containing oligomers and polymers can be prepared using stoichiometric or near stoichiometric ratios of the capping or functionalization reagent to polymer end-chain. | 2020-05-14 |
20200148799 | ETHYLENE-BASED POLYMERS AND PROCESSES FOR THE SAME - An ethylene-based polymer formed from reacting at least the following: ethylene and at least one asymmetrical polyene, and wherein the reaction takes place in the presence of at least one free-radical initiator; and wherein the at least one asymmetrical polyene is selected from Structure A, as described herein; Structure B, as described herein; or a combination of Structure A and Structure B. | 2020-05-14 |
20200148800 | Process for Producing Ethylene Copolymers - A process for producing an ethylene copolymer, the process including: (a) contacting ethylene with at least one polar comonomer in the presence of at least one modifier and at least one free radical initiator in a tubular reactor under polymerization conditions including a pressure of from 225 to 270 MPa; (b) injecting the at least one free radical initiator into the reactor at a plurality of reaction zones spaced along the length of the reactor, wherein each reaction zone comprises an inlet and an outlet; (c) maintaining the temperature at the inlet of each reaction zone at 150° C. or less, and the temperature at the outlet of each reaction zone is at least 177° C.; (d) controlling the modifier flow at a rate of from 0.02 to 0.986 wt % of the copolymer; and (e) recovering the ethylene copolymer from the tubular reactor, is provided. | 2020-05-14 |
20200148801 | PROCESS FOR PREPARING AN ACETOACETYL FUNCTIONAL POLYMER - A suspension process for preparing an acetoacetyl functional polymer and the acetoacetyl functional polymer made from the process suitable for aldehyde abatement. | 2020-05-14 |
20200148802 | METHOD FOR THE PREPARATION OF PHOTOALIGNING POLYMER MATERIALS AND COMPOSITIONS - The present invention relates to a novel method for the preparation of photoaligning polymer materials comprising aryl acrylic acid ester groups, to photoalignment compositions obtained by this process, to the use of the composition as orienting layer for liquid crystals and to non-structured and structured optical elements, electro-optical elements, multi-layer systems or in nanoelectronics comprising the compositions. | 2020-05-14 |
20200148803 | POLYMERIZABLE MULTIFUNCTIONAL ANTIMICROBIAL QUATERNARY AMMONIUM MONOMERS, METHODS OF SYNTHESIS, AND USES THEREOF - A polymerizable multifunctional antimicrobial monomer includes a quaternary ammonium cation group, wherein the quaternary ammonium cation ion group is bonded to functional groups and anions having structures chosen from the groups | 2020-05-14 |
20200148804 | Novel Synthetic Polymers and Crosslinked Hydrogel Systems - A novel synthetic functionalized backbone polymer is provided which is a polyanionic side-chain functionalized back-bone polymer comprising a hydrophilic backbone polymer functionalized with an activated alkene or epoxy group. The functionalized backbone polymer may be combined with a free or protected thiol-containing compound to form a crosslinked hydrogel having bio-medical application, and may additionally be combined with a hydrogel matrix to yield a hydrogel system useful for in vivo delivery of cells and other therapeutic agents. | 2020-05-14 |
20200148805 | CROSSLINKING AGENT AND FLUORINE-CONTAINING AROMATIC COMPOUND - A crosslinking agent includes a compound represented by a formula (1), | 2020-05-14 |
20200148806 | POLYURETHANE DISPERSIONS - The present disclosure is drawn to polyurethane dispersions. In one example, a polyurethane dispersion can include a polyurethane with a polymeric ionic side chain and a polymeric non-ionic side chain. The polyurethane can be formed of polymerized monomers including a diisocyanate, a first polymeric diol, and a second polymeric diol. The first polymeric diol can include a first polymer chain replacing a hydrogen atom of a thiol group of a 1-thioglycerol molecule. The first polymer chain can include a block of a polymerized ionic group-containing vinyl monomer. The second polymeric diol can include a second polymer chain replacing a hydrogen atom of a thiol group of a 1-thioglycerol molecule. The second polymer chain can include a block of a polymerized non-ionic vinyl monomer, and the second polymer chain can be devoid of ionic groups. | 2020-05-14 |
20200148807 | FLEXIBLE POLYURETHANE FOAM WITH SUSPENDED PARTICLES - The present disclosure describes a flexible polyurethane foam having suspended within its matrix particles of silicon dioxide, SiO | 2020-05-14 |
20200148808 | Silylated Polyurethanes and Methods for Preparing Thereof - The present invention discloses silylated polyurethanes obtainable by reacting at least one polyols, at least one polyisocyanates, at least one silicon-containing heterocycle of the general formula (I): | 2020-05-14 |
20200148809 | PROCESS FOR THE PREPARATION OF ALICYCLIC POLYISOCYANATE - The present invention relates to a polyisocyanate (P) of general formula (I), the method for preparing polysisocyanate (P) of general formula (I) and the use of polyisocyanate (P) of general formula (I) as crosslinking reagent in clearcoats. The method for preparing polyisocyanate (P) of general formula (I) comprises the reaction of a reaction mixture (RM), which comprises at least one cyclic isocyanate of general formula (IIIa), (IIIb), (IIIc), (IIId), (IIIe) and/or (IIIf) and at least one alcohol having at least two hydroxyl groups, to obtain polyisocyanate (P) of general formula (I). | 2020-05-14 |